Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PainReform ( (PRFX) ) has issued an update.
On February 17, 2025, PainReform Ltd. announced a strategic acquisition agreement with BladeRanger Ltd to acquire DeepSolar, an AI-driven solar analytics platform. This acquisition, expected to be finalized by the end of February 2025, marks a significant diversification move for PainReform, as it extends beyond its pharmaceutical roots into the rapidly growing solar energy market. The acquisition aims to enhance PainReform’s long-term growth by leveraging DeepSolar’s capabilities in optimizing solar energy assets and reducing operational costs, thus expanding its market reach in both commercial and residential solar sectors.
More about PainReform
PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics. The company’s proprietary extended-release drug-delivery system is designed to offer prolonged post-surgical pain relief, minimizing the need for repeated doses and potentially reducing opioid use.
YTD Price Performance: -12.96%
Average Trading Volume: 3,743,636
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.47M
Find detailed analytics on PRFX stock on TipRanks’ Stock Analysis page.
